Debates & Insight -

Latest Content

in Market Access
Innovative contracting in Europe – a Trojan horse?
June 29, 2019 Share
X
Innovative contracting in Europe – a Trojan horse?
https://pharmaphorum.com/market-access-2/innovative-contracting-in-europe-a-trojan-horse/
in Market Access
Launch excellence in a disrupted world – challenges & opportunities
May 17, 2019 Share
X
Launch excellence in a disrupted world – challenges & opportunities
https://pharmaphorum.com/market-access-2/launch-excellence-in-a-disrupted-world-challenges-opportunities/

Digital Debates

Innovative contracting in Europe – a Trojan horse?

Overview With pricing of drugs at the centre of political and social debate, the market access and pricing

Innovative contracting in Europe – a Trojan horse?

https://pharmaphorum.com/market-access-2/innovative-contracting-in-europe-a-trojan-horse/

Launch excellence in a disrupted world – challenges & opportunities

Overview The launch environment has undergone huge changes as the pharmaceutical industry’s focus has moved from primary care

Launch excellence in a disrupted world – challenges & opportunities

https://pharmaphorum.com/market-access-2/launch-excellence-in-a-disrupted-world-challenges-opportunities/

See all

Insights

Standing on the cusp of something great: How real-world data is poised to transform cancer care

REAL-WORLD EVIDENCE IN ONCOLOGY: Towards Innovative and Affordable Patient Care How can real world evidence (RWE) improve the

Standing on the cusp of something great: How real-world data is poised to transform cancer care

https://pharmaphorum.com/whitepapers/standing-cusp-something-great-real-world-data-poised-transform-cancer-care/

Pricing and Market Access Outlook 2018

This year’s edition of Pricing and Market Access Outlook, our first as IQVIA, identifies a trend towards models

Pricing and Market Access Outlook 2018

https://pharmaphorum.com/whitepapers/pricing-market-access-outlook-2018/

Pricing and market access – facts versus fiction

‘Pricing and Market Access Outlook: 2017 Edition’ includes fresh analysis from QuintilesIMS of market forces and pricing policy based on facts and figures behind approvals of new molecular entities in 2015.

Pricing and market access – facts versus fiction

https://pharmaphorum.com/whitepapers/pricing-market-access-facts-versus-fiction/

Big data in Life Sciences: the time for strategy is now

The ability to extract insights from big data is quickly becoming a key factor for competitive advantage in

Big data in Life Sciences: the time for strategy is now

https://pharmaphorum.com/whitepapers/life-sciences-brands-need-big-data-strategy-now/

Pricing & Market Access Outlook 2015/2016 Edition

Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten

Pricing & Market Access Outlook 2015/2016 Edition

https://pharmaphorum.com/whitepapers/pricing-market-access-outlook-2015-2016-edition/

Next-generation brand launches: Global health data and insights can transform your business

Life Sciences companies face challenges today in achieving their revenue forecast and return on investment from brand launches. Much

Next-generation brand launches: Global health data and insights can transform your business

https://pharmaphorum.com/whitepapers/next-generation-brand-launches-global-health-data-and-insights-can-transform-your-business/

Successful biopharma product launches depend upon market insights – driving competitive advantage through innovation

A major competitive advantage can be gained by companies that unlock the value hidden in the vast quantity

Successful biopharma product launches depend upon market insights – driving competitive advantage through innovation

https://pharmaphorum.com/whitepapers/successful-biopharma-product-launches-depend-upon-market-insights-driving-competitive-advantage-through-innovation/